A New State of Art
Conventionally, an individual’s risk of developing a Cardiovascular Disease (CVD) is assessed through their self-reported family history and lifestyle factors, such as physical activity levels, diet and smoking. However, this doesn’t consider their genetic susceptibility to CVDs.
When an individual is classed as an intermediate risk based on their lifestyle factors, it can be hard to determine if they will progress onto developing CVDs, which is where genotyping could become extremely useful.
What does the Heart DNA test cover?
Cardiovascular risks
TYPE III Hyperlipoproteinemia, Atrial Fibrillation, Coronary Artery Disease, Hypertension, Myocardial Infarction, Peripheral Arterial Disease and Sickle Cell Anaemia.
Drug responses
Beta Blocker Efficiency, Beta Blockers and LVEF Response, Metoprolol metabolism, Warfarin Sensitivity, Clopidogrel Metabolism, Verapamil and QTC Interval, Verapamil vs Atenolol, Simvastatin Uptake, Perindopril Metabolism and Caffeine Sensitivity.
Lipids Metabolism
Triglycerides, HDL Cholesterol, LDL Cholesterol and Gene X (Cholesterol lowering polymorphism).
Inherited Thrombophilia
Factor V Leiden, Prothrombin G20210A and MTHFR Variant.
Who is the test for?
Patients with a family history of a CVD.
Patients with existing cardiac conditions and would like to learn more about their conditions.
Patients who are on oestrogen therapy from combined oral contraceptives or HRT, or at risk of developing DVT.
Patients who are about to start medicating or currently on a treatment plan with reported side effects.
Anyone who would like to be more certain about their future cardiac health and make preventative lifestyle and behavioural changes.
Benefits for your patients
Informed Consent
The reports enable you to strengthen your patients' informed consent by giving them full knowledge of the potential consequences regarding their lifestyle choices, treatment options and the possible risks and benefits.
Prevention Over Treatment
The Heart DNA Test helps you suggest early interventions by identifying genetic risk factors for a range of conditions.
Treatment Compliance
Boost patients confidence in their prescribed treatment and improve adherence to medical advice, by uncovering genetic insights that changes the clinical dialogue from a population level advice to a more personal one.
Insightful Clinical Decisions
Have a more objective risk assessment by combining the patient's genetic risk profile and self-reported environmental factors. No report would ever be released without your prior review and context provision. The final decision is always yours.
Risk Management
Our pharmacogenetics panel predicts patients drug responses, reducing prescriptions of medication that is ineffective or causes adverse side effects.
How it works
Sign up as a partner
The whole process is online. You can create an account, fill in your speciality details and access your dashboard for all our learning resources.
Learn the science of the DNA
From your Resources tab, you will have access to clinical reporting manuals, publication copies and further readings to understand the mechanism of action of our tested DNA markers.
Offer the DNA test as part of
your routine health checks
The kits are barcoded with unique IDs which will assign your patients to your account.
Online Review
Access your patient results and self-reported questionnaire to make online reviews. Once completed, you can sign off the reports with your assessment.
Follow up, when needed
Patients can book appointments with you directly from their dashboard as well.
Expand your knowledge
We provide you with full training to develop your skills and create an environment that promotes your growth.
Qualifed Research
We translate clinical research on genetics and FDA adopted interpretation guidelines into practical formats to help you build your personalised advice to your patient.
Reporting Support
We also provide you with a clinical reporting manual to review cumulative risk profile, and on going support to answer all your questions from our network of leading geneticists.
Publications:
Shukla, H., Mason, J. L., & Sabyah, A. (2018). A Literature Review of Genetic Markers Conferring Impaired Response to Cardiovascular Drugs. American Journal of Cardiovascular Drugs, 18(4), 259–269.
Shukla, H., Mason, J. L., & Sabyah, A. (2018). Identifying genetic markers associated with susceptibility to cardiovascular diseases. Future Science OA, https://doi.org/10.4155/fsoa-2018-0031
Request a call back.
Start practicing precision medicine.